Concord Biotech Limited — Investor Meet, 01-08-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Concord Biotech reported strong Q1FY27 financial results: Revenue jumped 26% to Rs 257.5 Cr, EBITDA grew 34% to Rs 82.4 Cr, and PAT increased 31% to Rs 57.7 Cr. Exports surged 46% YoY, driving broad-based growth across products and geographies. The company secured USFDA approvals for Mycophenolate Mofetil and Tofacitinib Tablets. Operational highlights include commercial sales at Stellon Biotech and advanced customer engagement for injectables. Management expresses confidence in outperforming industry growth and strengthening leadership with a robust product pipeline.